evERA: FDA approves giredestrant with everolimus for ESR1-mutated advanced breast cancer

FDA,

FDAApproved

Giredestrant (Wilserdly) with everolimus

Adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, found by an FDA-authorized test, that recurred during or after adjuvant endocrine therapy or progressed on at least one endocrine-based treatment for metastatic disease

The trial behind it

evERA

10.0 months with giredestrant + everolimus

Median progression-free survival, ESR1-mutated

versus 5.5 months with standard endocrine therapy + everolimusHR 0.38 (95% CI 0.27–0.54); p<0.0001

27 % with giredestrant + everolimus

Response rate, ESR1-mutated

versus 14 % with standard endocrine therapy + everolimus95% CI 18–37 and 8–22

8.8 months with giredestrant + everolimus

Median progression-free survival, all patients

versus 5.5 months with standard endocrine therapy + everolimusHR 0.56 (95% CI 0.44–0.71); outside the approval

Dose Giredestrant 30 mg by mouth once daily, with or without food; everolimus as its own label directs

What did the FDA approve?

Giredestrant (Wilserdly, Genentech) is an estrogen receptor antagonist taken by mouth. The approval covers its use with everolimus for adults with ER-positive, HER2-negative, locally advanced or metastatic breast cancer carrying an ESR1 mutation, whose disease came back during or after adjuvant endocrine therapy, or progressed on at least one endocrine-based treatment for metastatic disease.

The FDA says it approved the application four weeks ahead of its goal date. The review ran under Project Orbis with Health Canada and Israel’s Ministry of Health, where applications may still be in progress.

What testing is needed?

Only tumors with an ESR1 mutation qualify, found by an FDA-authorized test. With the drug, the FDA authorized FoundationOne Liquid CDx, a blood test that reads circulating tumor DNA, as its companion diagnostic. In the trial, ESR1 status was tested centrally with this assay and counted only certain mutations in the receptor’s ligand-binding domain.

How was evERA designed?

evERA Breast Cancer (NCT05306340) is an open-label phase 3 trial in 373 adults with ER-positive, HER2-negative advanced breast cancer that had progressed or recurred after a CDK4/6 inhibitor plus endocrine therapy; 207 had ESR1-mutated tumors. Patients were randomized 1:1 to daily giredestrant 30 mg (183 patients) or their physician’s choice of exemestane, fulvestrant or tamoxifen (190 patients), each with everolimus 10 mg daily. Women before or around menopause, and men without a bilateral orchiectomy, also received a GnRH agonist.

The primary end point was progression-free survival assessed by the investigators, tested first in ESR1-mutated tumors and then in all patients. Genentech funded the trial.

MeasureGiredestrant + everolimusStandard endocrine therapy + everolimus
Patients (all)183190
Median progression-free survival, ESR1-mutated10.0 months (95% CI 8.1–12.9)5.5 months (95% CI 3.8–5.6)
Response rate, ESR1-mutated27% (95% CI 18–37)14% (95% CI 8–22)
Median progression-free survival, all patients8.8 months5.5 months
Any adverse event98.9%96.8%
Stomatitis47.3%48.9%
Diarrhea26.9%22.6%
Anemia23.6%21.0%
Hazard ratios for progression or death: 0.38 (95% CI 0.27–0.54) with ESR1 mutations; 0.56 (95% CI 0.44–0.71) in all patients. Source: FDA, November 16, 2026; Mayer EL, et al. NEJM 2026

What did the trial show?

In the 207 patients with ESR1-mutated tumors, giredestrant and everolimus kept the disease from progressing for a median of 10.0 months, against 5.5 months with standard endocrine therapy and everolimus (hazard ratio, 0.38; 95% CI, 0.27 to 0.54). Tumors responded in 27% and 14% of these patients. Overall survival data were not yet mature at the time of the analysis.

Across all 373 patients, including those without ESR1 mutations, median progression-free survival was 8.8 and 5.5 months (hazard ratio, 0.56; 95% CI, 0.44 to 0.71). The approval covers ESR1-mutated disease only.

What about safety?

Nearly every patient had an adverse event: 98.9% with giredestrant and everolimus, 96.8% with standard therapy and everolimus. The investigators report stomatitis (47.3% and 48.9%), diarrhea (26.9% and 22.6%) and anemia (23.6% and 21.0%) as the most frequent.

The FDA lists the most common adverse reactions, in 20% of patients or more, as stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis and nausea. Giredestrant’s label warns of bradycardia and embryo-fetal toxicity.

What else is approved for ESR1-mutated breast cancer?

Three other estrogen receptor antagonists are FDA-approved for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer:

  • Elacestrant, January 27, 2023: after at least one line of endocrine therapy
  • Imlunestrant, September 25, 2025: after at least one line of endocrine therapy
  • Camizestrant, accelerated approval on September 4, 2026: with a CDK4/6 inhibitor, when an ESR1 mutation is found during aromatase inhibitor and CDK4/6 inhibitor therapy

All three use the Guardant360 CDx test to find the mutation.

Sources

  1. FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. US Food and Drug Administration. November 16, 2026.
  2. Giredestrant plus everolimus in advanced breast cancer. Mayer EL, Tolaney SM, Martín M, et al. N Engl J Med. 2026;395(13):1285-1298.
  3. FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. US Food and Drug Administration. January 27, 2023.
  4. FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. US Food and Drug Administration. September 25, 2025.
  5. FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer. US Food and Drug Administration. September 4, 2026.

Take-home

The FDA approved giredestrant with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after endocrine therapy, and authorized FoundationOne Liquid CDx to find the mutation. In the phase 3 evERA trial, median progression-free survival with ESR1 mutations was 10.0 months, against 5.5 months with standard endocrine therapy and everolimus.

Read the source in FDA

More on breast cancer